Share ownership argenx SE

ARGX

NL0010832176

Biotechnology & Medical Research

Real-time Euronext Bruxelles Other stock markets 11:00:10 11/06/2026 BST			5-day change	1st Jan Change
759.80 ^EUR	-0.42%		+4.25%	+6.00%

06-09	Argenx SE Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 04:00 PM
06-08	William O'Neil Initiates argenx at Buy	MT

Share class: argenx SE

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	62,187,771	62,187,771 ( 100 %)	0	100 %

Major shareholders: argenx SE

Name	Stocks	%	Valuation
Norges Bank Investment Management 2.774 %	1,716,514	2.774 %	1 433 M €
FMR Investment Management (UK) Ltd. 0.1839 %	113,833	0.1839 %	95 M €
Sjunde AP-fonden 0.1429 %	88,442	0.1429 %	74 M €
Tim van Hauwermeiren 0.1165 %	72,095	0.1165 %	60 M €
Lazard Asset Management Ltd. 0.0962 %	59,504	0.0962 %	50 M €
HBM Partners AG (Investment Management) 0.0848 %	52,500	0.0848 %	44 M €
State Street Global Advisors Ltd. 0.0764 %	47,299	0.0764 %	39 M €
Fineco Asset Management DAC 0.0625 %	38,672	0.0625 %	32 M €
OFI Invest Asset Management SA 0.0595 %	36,826	0.0595 %	31 M €
T. Rowe Price International Ltd. 0.0573 %	35,486	0.0573 %	30 M €
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Stocks	%	Valuation
Fidelity Management & Research Co. LLC 8.065 %	4,991,034	8.065 %	4 172 M €
T. Rowe Price International Ltd. 5.454 %	3,374,955	5.454 %	2 821 M €
Janus Henderson Investors US LLC 4.107 %	2,541,732	4.107 %	2 125 M €
T. Rowe Price Associates, Inc. (IM) 3.651 %	2,259,352	3.651 %	1 889 M €
Capital Research & Management Co. (World Investors) 3.646 %	2,256,216	3.646 %	1 886 M €
Artisan Partners Holdings LP 2.372 %	1,467,982	2.372 %	1 227 M €
Wellington Trust Co., NA 1.651 %	1,021,457	1.651 %	854 M €
Avoro Capital Advisor LLC 1.616 %	1,000,000	1.616 %	836 M €
T. Rowe Price International Ltd. 1.289 %	797,985	1.289 %	667 M €
RTW Investments LP 1.146 %	709,446	1.146 %	593 M €
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	51.07%
Others	5.32%
SEI Investments Co.	0.47%
Individuals	0.18%
Manulife Financial Corp.	0.08%
State Street Corp.	0.01%
Unknown	42.87%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	40.79%
United Kingdom	9.1%
Norway	2.82%
Canada	0.83%
France	0.69%
Ireland	0.51%
Switzerland	0.47%
Germany	0.31%
Sweden	0.3%
Luxembourg	0.23%
Individuals	0.18%
Netherlands	0.15%
Belgium	0.13%
Japan	0.11%
Italy	0.1%
Australia	0.09%
Spain	0.06%
Austria	0.06%
Taiwan	0.03%
Finland	0.03%
Denmark	0.03%
Singapore	0.02%
Hong Kong	0.02%
China	0.02%
Mexico	0.01%
New Zealand	0.01%
South Africa	0.01%
Greece	0.01%

Based on 1000 largest holdings

argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises.

Employees

1,863

Sector

Biotechnology & Medical Research

Calendar

Earnings release - Q2 2026

More about the company